155 related articles for article (PubMed ID: 7632952)
1. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.
Mason DY; Cordell JL; Brown MH; Borst J; Jones M; Pulford K; Jaffe E; Ralfkiaer E; Dallenbach F; Stein H
Blood; 1995 Aug; 86(4):1453-9. PubMed ID: 7632952
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
Astsaturov IA; Matutes E; Morilla R; Seon BK; Mason DY; Farahat N; Catovsky D
Leukemia; 1996 May; 10(5):769-73. PubMed ID: 8656670
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.
Pilozzi E; Pulford K; Jones M; Müller-Hermelink HK; Falini B; Ralfkiaer E; Pileri S; Pezzella F; De Wolf-Peeters C; Arber D; Stein H; Mason D; Gatter K
J Pathol; 1998 Oct; 186(2):140-3. PubMed ID: 9924428
[TBL] [Abstract][Full Text] [Related]
4. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.
Korkolopoulou P; Cordell J; Jones M; Kaklamanis L; Tsenga A; Gatter KC; Mason DY
Histopathology; 1994 Jun; 24(6):511-5. PubMed ID: 7520411
[TBL] [Abstract][Full Text] [Related]
5. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
[TBL] [Abstract][Full Text] [Related]
6. CD79: a review.
Chu PG; Arber DA
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):97-106. PubMed ID: 11396639
[TBL] [Abstract][Full Text] [Related]
7. Transcription and protein expression of mb-1 and B29 genes in human hematopoietic malignancies and cell lines.
Verschuren MC; Comans-Bitter WM; Kapteijn CA; Mason DY; Brouns GS; Borst J; Drexler HG; van Dongen JJ
Leukemia; 1993 Dec; 7(12):1939-47. PubMed ID: 8255092
[TBL] [Abstract][Full Text] [Related]
8. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens.
Arber DA; Jenkins KA
Am J Clin Pathol; 1996 Oct; 106(4):462-8. PubMed ID: 8853033
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols.
Kappelmayer J; Gratama JW; Karászi E; Menéndez P; Ciudad J; Rivas R; Orfao A
J Immunol Methods; 2000 Aug; 242(1-2):53-65. PubMed ID: 10986389
[TBL] [Abstract][Full Text] [Related]
10. The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation.
Mason DY; van Noesel CJ; Cordell JL; Comans-Bitter WM; Micklem K; Tse AG; van Lier RA; van Dongen JJ
Eur J Immunol; 1992 Oct; 22(10):2753-6. PubMed ID: 1396979
[TBL] [Abstract][Full Text] [Related]
11. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
12. Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia.
Thompson AA; Talley JA; Do HN; Kagan HL; Kunkel L; Berenson J; Cooper MD; Saxon A; Wall R
Blood; 1997 Aug; 90(4):1387-94. PubMed ID: 9269755
[TBL] [Abstract][Full Text] [Related]
13. Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex.
Vasile S; Coligan JE; Yoshida M; Seon BK
Mol Immunol; 1994 Apr; 31(6):419-27. PubMed ID: 7514267
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.
Blakolmer K; Vesely M; Kummer JA; Jurecka W; Mannhalter C; Chott A
Mod Pathol; 2000 Jul; 13(7):766-72. PubMed ID: 10912936
[TBL] [Abstract][Full Text] [Related]
15. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
Epstein AL; Marder RJ; Winter JN; Fox RI
J Immunol; 1984 Aug; 133(2):1028-36. PubMed ID: 6376628
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias.
Hashimoto M; Yamashita Y; Mori N
J Pathol; 2002 Jul; 197(3):341-7. PubMed ID: 12115880
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections.
Chadburn A; Husain S; Knowles DM
Hum Pathol; 1992 Aug; 23(8):940-7. PubMed ID: 1353748
[TBL] [Abstract][Full Text] [Related]
18. Acute lymphoblastic leukaemia: correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens.
Kröber SM; Greschniok A; Kaiserling E; Horny HP
Mol Pathol; 2000 Apr; 53(2):83-7. PubMed ID: 10889907
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79b (Ig-beta/B29) RNA transcripts in human B cells.
Hashimoto S; Chiorazzi N; Gregersen PK
Mol Immunol; 1995 Jun; 32(9):651-9. PubMed ID: 7643857
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.
Adams H; Liebisch P; Schmid P; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):96-101. PubMed ID: 18838917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
